Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicenter study

INTRODUCTION: HER2 mutations occur in 1-3% of lung adenocarcinomas. With increasing use of next-generation sequencing at diagnosis, more patients with HER2-mutant tumors are presenting for treatment. Few data are available to describe the clinical course and outcomes of these patients when treated w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Lai, W. Victoria, Lebas, Louisiane, Barnes, Tristan A., Milia, Julie, Ni, Ai, Gautschi, Oliver, Peters, Solange, Ferrara, Roberto, Plodkowski, Andrew J., Kavanagh, John, Sabari, Joshua K., Clarke, Stephen J., Pavlakis, Nick, Drilon, Alexander, Rudin, Charles M., Arcila, Maria E., Leighl, Natasha B., Shepherd, Frances A., Kris, Mark G., Mazières, Julien, Li, Bob T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6426688/
https://ncbi.nlm.nih.gov/pubmed/30685684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2018.11.030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados